×
Jasper Therapeutics EBIT 2020-2025 | JSPR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Jasper Therapeutics ebit from 2020 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
Jasper Therapeutics EBIT 2020-2025 | JSPR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Jasper Therapeutics ebit from 2020 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.8B
Amgen (AMGN)
$154.9B
Gilead Sciences (GILD)
$140.2B
Vertex Pharmaceuticals (VRTX)
$100.3B
Bristol Myers Squibb (BMY)
$96B
GSK (GSK)
$80.8B
CSL (CSLLY)
$67.1B
Regeneron Pharmaceuticals (REGN)
$61.5B
Alnylam Pharmaceuticals (ALNY)
$58.5B
Argenex SE (ARGX)
$43.6B
Insmed (INSM)
$28.8B
BioNTech SE (BNTX)
$24B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$19.4B
Incyte (INCY)
$16.5B
Genmab (GNMSF)
$16.5B
Genmab (GMAB)
$16B
Illumina (ILMN)
$15.4B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.3B
Exelixis (EXEL)
$10.1B
Moderna (MRNA)
$9.4B
Verona Pharma American Depositary Share (VRNA)
$9.2B
Exact Sciences (EXAS)
$9B
Bio-Techne Corp (TECH)
$8.6B
Halozyme Therapeutics (HALO)
$8.6B
Guardant Health (GH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B